Zota Health Care Acquires 10 Lakh Shares in Subsidiary Curexis Ventures
Zota Health Care acquired 10,00,000 equity shares in its subsidiary Curexis Ventures for ₹2 crore. The acquisition was made via a rights issue at ₹20 per share. Curexis, involved in drug manufacturing and retail pharmacy, had a turnover of ₹1.18 Lakhs in FY25-26.
The acquisition involves a subsidiary and is described as a strategic investment for expansion and working capital support. While it supports growth, the immediate financial impact is limited given the subsidiary's current turnover.
The acquisition of shares in a wholly-owned subsidiary is a strategic move that does not inherently represent a significant positive or negative development for the company's overall financial performance at this stage.
Zota Health Care Limited has announced the acquisition of 10,00,000 equity shares in its wholly-owned subsidiary, Curexis Ventures Private Limited, through a subscription to a rights issue. The acquisition, which took place on June 22, 2026, was made for a cash consideration of ₹20.00 per equity share, including a premium of ₹10.00 per share, aggregating to a total of ₹2,00,00,000.00.
Curexis Ventures Private Limited is involved in drug manufacturing, development, and marketing, and operates retail pharmacy stores under the brand name “SKIA”. For the Financial Year 2025-26, Curexis reported a turnover of ₹1.18 Lakhs and a total paid-up share capital of ₹1 Lakh. The company was incorporated on February 25, 2025.
This strategic investment by Zota Health Care is aimed at expanding the SKIA store network and mitigating the working capital requirements of Curexis. The acquisition does not fall within related party transactions, and the transaction has been conducted on an arm's length basis.
What to do with a filing like this
Zota Health Care LImited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zota Health Care LImited. Read the original for the full detail.